In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals, with a price target of $35.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight Eton Pharmaceuticals’ promising growth trajectory. The company reported a significant increase in revenues for the third quarter of 2025, surpassing expectations and demonstrating strong performance in its product relaunches, particularly Increlex and Galzin. This growth is expected to continue, with a projected 116% year-over-year revenue increase for 2025, driven by the addition of new products and strategic operational improvements.
Looking forward, Eton Pharmaceuticals has several catalysts that could further enhance its financial outlook. The anticipated approval and launch of ET-600 in 2026, along with potential acquisition transactions, are expected to contribute positively to the company’s revenue stream. Additionally, planned label expansions for Khindivi and Increlex could unlock new market opportunities, supporting long-term growth. With a robust cash position and a strategic focus on expanding its commercial portfolio, Eton Pharmaceuticals is well-positioned for sustained growth, justifying the Buy rating.
Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Evaxion Biotech, and Delcath Systems. According to TipRanks, Ramakanth has an average return of 22.5% and a 45.11% success rate on recommended stocks.